| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.30▼ | 1.30▲ | 1.30▲ | 1.28▲ | 1.29▲ |
| MA10 | 1.30▲ | 1.29▲ | 1.28▲ | 1.28▲ | 1.38▼ |
| MA20 | 1.30▲ | 1.27▲ | 1.26▲ | 1.31▼ | 1.19▲ |
| MA50 | 1.29▲ | 1.26▲ | 1.28▲ | 1.38▼ | 0.98▲ |
| MA100 | 1.26▲ | 1.28▲ | 1.23▲ | 1.16▲ | 1.14▲ |
| MA200 | 1.26▲ | 1.24▲ | 1.37▼ | 1.01▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | 0.003▲ | 0.007▲ | 0.004▲ | -0.009▼ |
| RSI | 54.871▲ | 62.551▲ | 59.656▲ | 48.491▼ | 55.800▲ |
| STOCH | 83.333▲ | 84.028▲ | 90.787▲ | 69.406 | 44.509 |
| WILL %R | -33.333 | -7.692▲ | -5.000▲ | -20.690▲ | -53.723 |
| CCI | 20.588 | 89.465 | 91.557 | 71.693 | -19.983 |
|
Thursday, April 24, 2025 09:05 AM
Study shows Lucid's EsoGuard test detects esophageal precancer in at-risk patients without symptoms. Read more here.
|
|
Thursday, April 24, 2025 05:01 AM
NEW YORK, April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...
|
|
Monday, April 21, 2025 02:01 PM
Lucid Diagnostics Inc (LUCD) ends 2024 with significant milestones in sales and reimbursement, despite facing revenue and ASP hurdles.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/05/25 | 1.30 | 1.30 | 1.30 | 1.30 | 11,163 |
| 01/05/25 | 1.26 | 1.31 | 1.24 | 1.29 | 773,504 |
| 30/04/25 | 1.24 | 1.29 | 1.19 | 1.25 | 1,077,801 |
| 29/04/25 | 1.27 | 1.295 | 1.215 | 1.265 | 856,293 |
| 28/04/25 | 1.33 | 1.3453 | 1.25 | 1.28 | 755,323 |
| 25/04/25 | 1.34 | 1.36 | 1.26 | 1.33 | 1,290,887 |
| 24/04/25 | 1.32 | 1.36 | 1.27 | 1.33 | 1,907,144 |
| 23/04/25 | 1.29 | 1.32 | 1.25 | 1.29 | 1,166,419 |
| 22/04/25 | 1.21 | 1.29 | 1.195 | 1.28 | 884,731 |
| 21/04/25 | 1.22 | 1.22 | 1.17 | 1.20 | 583,059 |
|
|
||||
|
|
||||
|
|